Artwork
iconShare
 
Manage episode 522221209 series 2409126
Content provided by The Lancet. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.

  continue reading

701 episodes